REGULAR CONTENT
Final ID
465
Type
Original Scientific Research-Poster Only
Authors
S Sanamandra1, C Too2
Institutions
1singapore general hospital, Sinagpore, Sinagpore, 2Singapore General Hospital, Singapore, Singapore
Purpose
Sonazoid is a new ultrasound contrast agent that allows for Kupffer phase imaging. Liver tumors will demonstrate Kupffer phase defects due to the lack of normal Kupffer cells. Unlike other agents, the prolonged Kupffer phase imaging allows for adequate time for ultrasound-guided targeting of lesions. We aim to investigate the efficacy of Sonazoid contrast-enhanced ultrasound for radiofrequency ablation (RFA) of hepatic tumors in our local population.
Materials & Methods
This is a retrospective review of 38 patients who underwent Sonazoid contrast-enhanced ultrasound-guided RFA of hepatic tumors from March to December of 2015. Pre-procedural Sonazoid-enhanced ultrasound scans were performed and images were compared with pre-treatment cross-sectional study images.
Results
There were 55 suspicious lesions detected on pre-treatment studies and deemed suitable for RFA. These range from 0.7 to 3.0 cm in size and were not seen with grey-scale ultrasound. 43 (78.2%) were identified on Sonazoid-enhanced ultrasound. Of the 12 which did not demonstrate Kupffer phase defects, 3 were from the same patient. 2 were found in subdiaphragmatic positions and one was indeterminate for a dysplastic nodule on pre-procedural MRI. The inability to visualise the other 9 may be related to body habitus or background of fatty change. 43 lesions were followed up with advanced imaging at a median interval of around one month. Complete ablation rate was 90.6%.
Conclusions
Sonazoid is a useful adjunct when targeting lesions that are poorly visualized on grey-scale ultrasonography during RFA of liver tumors.
Final ID
465
Type
Original Scientific Research-Poster Only
Authors
S Sanamandra1, C Too2
Institutions
1singapore general hospital, Sinagpore, Sinagpore, 2Singapore General Hospital, Singapore, Singapore
Purpose
Sonazoid is a new ultrasound contrast agent that allows for Kupffer phase imaging. Liver tumors will demonstrate Kupffer phase defects due to the lack of normal Kupffer cells. Unlike other agents, the prolonged Kupffer phase imaging allows for adequate time for ultrasound-guided targeting of lesions. We aim to investigate the efficacy of Sonazoid contrast-enhanced ultrasound for radiofrequency ablation (RFA) of hepatic tumors in our local population.
Materials & Methods
This is a retrospective review of 38 patients who underwent Sonazoid contrast-enhanced ultrasound-guided RFA of hepatic tumors from March to December of 2015. Pre-procedural Sonazoid-enhanced ultrasound scans were performed and images were compared with pre-treatment cross-sectional study images.
Results
There were 55 suspicious lesions detected on pre-treatment studies and deemed suitable for RFA. These range from 0.7 to 3.0 cm in size and were not seen with grey-scale ultrasound. 43 (78.2%) were identified on Sonazoid-enhanced ultrasound. Of the 12 which did not demonstrate Kupffer phase defects, 3 were from the same patient. 2 were found in subdiaphragmatic positions and one was indeterminate for a dysplastic nodule on pre-procedural MRI. The inability to visualise the other 9 may be related to body habitus or background of fatty change. 43 lesions were followed up with advanced imaging at a median interval of around one month. Complete ablation rate was 90.6%.
Conclusions
Sonazoid is a useful adjunct when targeting lesions that are poorly visualized on grey-scale ultrasonography during RFA of liver tumors.